Muscle Loss on Semaglutide: What the STEP Trials Actually Show
TL;DR
- Muscle loss on semaglutide is real — but the robust number is smaller than the one that gets screenshotted: across 22 trials, about 25% of total weight lost was lean tissue, in people running no preservation strategy.
- The “nearly half your weight loss is muscle” figure traces to a single small exploratory substudy. The pooled data across thousands of participants lands near 25%.
- These fractions aren’t unique to GLP-1. They match what aggressive weight loss does by any method when protein and training aren’t in place.
- A documented case series of GLP-1 users who trained and ate enough protein preserved or gained lean mass. The default outcome is not the only outcome.
- The trial data sets the stakes. The three levers — protein, training, rate of loss — are the response.
Losing muscle on semaglutide is a legitimate concern, and anyone telling you it isn’t hasn’t read the trial data carefully. The concern is real. So is the response — but it starts with the data, not with reassurance, and not with the most alarming number somebody pulled out of a substudy.
This article covers what the trials actually showed on body composition, how those numbers compare to other weight loss approaches, and what they mean for someone who cares about keeping what they’ve built. If you want the protocol itself rather than the evidence behind it, the free GLP-1 Starter Framework lays out all three levers as a system you can run from your first injection.
What the STEP 1 Trial Body Composition Data Actually Shows
STEP 1 is the landmark semaglutide weight loss trial: 1,961 non-diabetic adults with BMI ≥30 (or ≥27 with comorbidity), 68 weeks of semaglutide 2.4mg/week versus placebo, mean weight loss of 14.9% in the treatment arm (Wilding JPH et al. NEJM. 2021;384:989-1002).
The headline weight loss figure gets cited everywhere. What rarely gets cited is what that weight loss was made of — and this is where most coverage goes wrong, in both directions.
The DXA body composition substudy of STEP 1 (140 participants) found that lean body mass fell 9.7%, while lean mass as a proportion of total body weight actually rose about 3.0 percentage points (Wilding JPH et al. Journal of the Endocrine Society. 2021). Read those two numbers together: absolute lean mass dropped, but fat dropped faster, so the body got leaner as a ratio even as it lost some muscle. Both things are true, and which one matters depends on your goals — a point the deeper STEP 1 breakdown takes apart in full.
For the better central estimate of how much of GLP-1 weight loss is lean tissue, the strongest data is a pooled analysis of 22 randomized controlled trials involving 2,258 participants (Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Metabolism. 2025;164:156113). That analysis found lean mass comprising approximately 25% of total weight lost — a lean mass reduction of roughly 0.86 kg against 3.55 kg of total weight loss — and, notably, that the percentage of the body that was lean did not worsen. That ~25% is the number to anchor on.
Estimates do vary. A 2024 review documents trial-to-trial ranges that run from around 15% of weight lost in some studies up toward 40% or higher in others, driven by population, drug, dose, trial length, and how lean mass was measured (Neeland IJ, Linge J, Birkenfeld AL. Diabetes Obes Metab. 2024;26 Suppl 4:16-27). The same review argues the muscle change may be partly adaptive — muscle quality improving even as quantity slips. The honest read: roughly 25% on average, higher in some settings, and meaningfully reducible. None of it is negligible for someone who trains.
What the SURMOUNT-1 Trial Shows for Tirzepatide
SURMOUNT-1 enrolled 2,539 non-diabetic adults with BMI ≥30 (or ≥27 with comorbidity), randomized to tirzepatide (5, 10, or 15 mg weekly) or placebo for 72 weeks. At the highest dose, mean weight loss was 20.9% (Jastreboff AM et al. NEJM. 2022;387:205-216).
The body composition signal worth sitting with isn’t the percentage — it’s the absolute number. Because total weight loss with tirzepatide runs substantially higher than semaglutide (20.9% vs 14.9%), a similar lean mass fraction still means more lean tissue gone in absolute terms. Greater efficacy demands greater vigilance, not less. How tirzepatide and semaglutide actually compare on body composition goes through the drug-versus-drug data, including the real-world signal that tirzepatide may cost slightly more lean mass.
How These Numbers Compare to Other Weight Loss Approaches
The GLP-1 lean mass fractions are not uniquely bad. They sit inside the range seen during aggressive weight loss without a preservation strategy, across interventions. Diet-induced weight loss without resistance training generally produces lean mass fractions in the 25–35% band, and the GLP-1 pooled figure falls within it (Neeland IJ, Linge J, Birkenfeld AL. Diabetes Obes Metab. 2024;26 Suppl 4:16-27). GLP-1 is subject to the same physics as any other aggressive deficit — nothing more, nothing less.
What changes those numbers is structured resistance training plus adequate protein. A case series by Tinsley GM and Nadolsky S (Sage Open Med Cases. 2025) documented three GLP-1 users who trained three to five days per week with protein intakes of 1.6–2.3g per kg of fat-free mass — all three preserved or gained lean mass during treatment. Three people is a case series, not an RCT, and the framing matters: it illustrates possibility, not average outcomes. But it is directionally consistent with what exercise physiology predicts, and it points at the mechanism — which why GLP-1 doesn’t cause muscle loss directly covers in full.
What You Should Do With These Numbers
The trial data serves one purpose: it calibrates the stakes. A lean mass fraction around 25%, in populations with no structured preservation protocol, tells you that lean mass loss is the default outcome when the three levers aren’t pulled — not a fringe risk.
The practical response isn’t alarm. It’s specificity. Before I started, I spent weeks reading on muscle retention and growth — going deep into the mechanisms of hypertrophy to understand what actually drives the body to build and hold muscle, so I could plan to produce muscle growth across the 41-week deficit ahead of me rather than just hope to limp out of it with what I had. That research is the reason I treated lean mass as something to engineer, not something to cross my fingers about. Your mileage may vary, but going in with a plan built on the mechanism beats reacting to the scale.
From there it’s diagnostic:
If you’re not yet on GLP-1, get a baseline DEXA scan before starting. Without a reference point, you can’t know whether lean mass held.
If you’re on GLP-1 with no preservation protocol, start tracking protein and add resistance training. The trial fractions came from people doing neither.
If you’re already tracking and training, use the data as a target to beat. A DEXA at 12 weeks showing a lean mass fraction under 25% means the protocol is working. Above ~35% means something in execution needs adjustment. The three variables that decide the split is where those adjustments get specific, and the full body recomposition framework ties them together.
Why Standard GLP-1 Prescribing Doesn’t Address This
Prescribers focus on what a prescribing visit is built for: weight loss, glycemic control, cardiovascular risk, side effect management. Lean mass preservation strategy isn’t part of that consult — not because it doesn’t matter, but because it falls outside the scope of what the visit is designed to do. The STEP and SURMOUNT trials reflect the same design: they measured weight loss and safety, enrolled participants with general lifestyle counseling, and produced body composition results that show what happens when nobody is managing the levers.
The data tells you what happened with no specific muscle preservation strategy. It doesn’t tell you what happens when protein is adequate, training is consistent, and rate of loss is managed. Those three levers are what this site is built around.
Get the Framework
Download the free GLP-1 Starter Framework — the three-lever system for losing fat without losing muscle. It turns protein intake, resistance training, and rate of loss into a protocol you can run from your first injection.
Download the free GLP-1 Starter Framework →
If you want the evidence in depth — every trial, properly caveated, in one place — that’s what GLP-1 & Body Composition: What the Research Actually Says is built for.
FAQ
How much muscle do you lose on semaglutide?
The most robust estimate, pooled across 22 randomized trials, is that about 25% of total weight lost on GLP-1 therapy is lean mass — roughly 0.86 kg of lean against 3.55 kg of total weight loss on average (Karakasis et al., Metabolism, 2025). Individual results vary widely with protein intake, training, and how fast the weight comes off. People running a deliberate preservation protocol routinely beat that 25% figure, sometimes preserving lean mass entirely.
Is muscle loss on Ozempic permanent?
Lost lean mass isn’t gone forever, but there’s no automatic catch-up. Muscle lost during a deficit has to be deliberately rebuilt afterward through resistance training and adequate protein, which takes time and a caloric surplus or at least maintenance. The better strategy is preventing the loss in the first place, since preserving existing muscle during weight loss is far less work than rebuilding it later.
Does everyone lose muscle on GLP-1?
No. The trial fractions describe populations given no structured preservation strategy — no protein targets, no resistance training, no rate management. A documented case series of GLP-1 users who trained three to five days weekly and ate 1.6–2.3g protein per kg of fat-free mass preserved or gained lean mass (Tinsley and Nadolsky, 2025). The loss is a default, not a destiny.
How do I know if I’m losing muscle or fat on semaglutide?
Scale weight can’t tell you — it reports total mass, not composition. A DEXA scan at baseline and again at 12 weeks gives an objective read on fat versus lean. Between scans, strength is the best proxy: if your squat, bench, and row hold within about 5% of baseline while weight drops, lean mass is almost certainly being preserved. A progressive strength decline is the warning sign.
Can you build muscle while on semaglutide?
Yes, though it’s harder than simple preservation. Net muscle gain during a deficit is most achievable for people new to resistance training and those carrying significant excess body fat — which describes many GLP-1 users. For most, the right primary target is preservation: hold lean mass while fat drops. Building muscle is the upside, not the baseline expectation.
Nothing on this site constitutes medical advice. I’m not a physician, and this blog documents my own research and experience. Consult a qualified healthcare provider for decisions about medication, dosing, or treatment.
— Ryan Mercer | MetabolicMale.com | ryanmercer@metabolicmale.com
Citations:
Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021;384:989-1002.
Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 body composition substudy). Journal of the Endocrine Society. 2021.
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022;387:205-216.
Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025;164:156113.
Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26 Suppl 4:16-27.
Tinsley GM, Nadolsky S. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. Sage Open Med Cases. 2025.
